INOVIO Pharmaceuticals Inc (Nasdaq:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced on Thursday the pricing of an underwritten public offering of 58,747,235 shares of its common stock at a public offering price of USD1.05 per share of common stock and pre-funded warrants to purchase 12,681,337 shares of common stock at an offering price of USD1.049 per pre-funded warrant, in each case before underwriting discounts and commissions.

INOVIO also granted the underwriters an option for a period of 30 days to purchase up to 10,714,285 additional shares of the company's common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about 9 November 2026, subject to the satisfaction of customary closing conditions.

Gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, and excluding any exercise of the underwriter's option to purchase additional shares of common stock, are expected to be approximately USD75m.

Jefferies and Piper Sandler are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.